Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Braze, Inc.BRZE · Entity 4102 | 10% owner | February 08, 2022 | February 09, 2022 |
| GLAUKOS CorpGKOS · Entity 3510 | Director | August 19, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Braze, Inc.
Report date February 08, 2022 · Filed February 09, 2022
Jointly reported with InterWest Management Partners X, LLC, INTERWEST PARTNERS X LP, NASR KHALED, Desai Keval
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectBy: InterWest Partners X, LP | 3,394,219 |
Reported balance
After 2022-02-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-02-08 · Conversion · Acquired 3,394,219 · Balance 3,394,219 F1: Each share of Class B Common Stock, par value $0.001 per share (the "Class B Common Stock"), converted into one share of Class A Common Stock, par value $0.001 per share (the "Class A Common Stock"), at the option of the holder. F2: The reported securities are owned directly by InterWest Partners X, L.P. ("IW X"). The general partner of IW X is InterWest Management Partners X, LLC ("IMP X") and may be deemed to beneficially own the shares held by IW X. Gilbert H. Kliman is the managing director of IMP X and Keval Desai and Khaled A. Nasr are venture members of IMP X. The managing director and venture members of IMP X share voting and investment control with respect to the securities held by IW X. Each of IMP X, Mr. Kliman, Mr. Desai and Mr. Nasr disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectBy: InterWest Partners X, LP | 0 |
Reported balance
After 2022-02-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-08 · Conversion · Disposed 3,394,219 · Balance 0 F1: Each share of Class B Common Stock, par value $0.001 per share (the "Class B Common Stock"), converted into one share of Class A Common Stock, par value $0.001 per share (the "Class A Common Stock"), at the option of the holder. F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock (A) at any time at the option of the Reporting Person or (B) automatically upon the occurrence of the following: (1) the transfer of such share of Class B Common Stock, except for certain transfers whereby the Reporting Person continues to hold sole voting and dispositive power with respect to each such share, (2) the death of a Class B common stockholder who is a natural person, (3) the last trading day of the fiscal quarter immediately following the fifth anniversary of the Issuer's initial public offering, (4) the date specified by affirmative vote of the holders of a majority of the outstanding shares of Class B common stock and (5) the last trading day of the fiscal quarter during which the then outstanding shares of Class B Common Stock first represent less than 10% of the aggregate number of shares of the then outstanding Class A Common Stock and Class B Common Stock. F2: The reported securities are owned directly by InterWest Partners X, L.P. ("IW X"). The general partner of IW X is InterWest Management Partners X, LLC ("IMP X") and may be deemed to beneficially own the shares held by IW X. Gilbert H. Kliman is the managing director of IMP X and Keval Desai and Khaled A. Nasr are venture members of IMP X. The managing director and venture members of IMP X share voting and investment control with respect to the securities held by IW X. Each of IMP X, Mr. Kliman, Mr. Desai and Mr. Nasr disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock, par value $0.001 per share (the "Class B Common Stock"), converted into one share of Class A Common Stock, par value $0.001 per share (the "Class A Common Stock"), at the option of the holder.
F2: The reported securities are owned directly by InterWest Partners X, L.P. ("IW X"). The general partner of IW X is InterWest Management Partners X, LLC ("IMP X") and may be deemed to beneficially own the shares held by IW X. Gilbert H. Kliman is the managing director of IMP X and Keval Desai and Khaled A. Nasr are venture members of IMP X. The managing director and venture members of IMP X share voting and investment control with respect to the securities held by IW X. Each of IMP X, Mr. Kliman, Mr. Desai and Mr. Nasr disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein.
F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock (A) at any time at the option of the Reporting Person or (B) automatically upon the occurrence of the following: (1) the transfer of such share of Class B Common Stock, except for certain transfers whereby the Reporting Person continues to hold sole voting and dispositive power with respect to each such share, (2) the death of a Class B common stockholder who is a natural person, (3) the last trading day of the fiscal quarter immediately following the fifth anniversary of the Issuer's initial public offering, (4) the date specified by affirmative vote of the holders of a majority of the outstanding shares of Class B common stock and (5) the last trading day of the fiscal quarter during which the then outstanding shares of Class B Common Stock first represent less than 10% of the aggregate number of shares of the then outstanding Class A Common Stock and Class B Common Stock.
GLAUKOS Corp
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,406 |
Last balance in matching sequence
After 2026-08-19 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-08-19 · Exercise / conversion · Acquired 2,500 · Balance 39,906 F1: Includes 2,501 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Row 2 · 2026-08-19 · Sale · Disposed 2,500 · Balance 37,406 F1: Includes 2,501 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.77 · Expires 2027-12-13 | Direct | 12,500 |
Reported balance
After 2026-08-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-19 · Exercise / conversion · Disposed 2,500 · Balance 12,500 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 2,501 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person.
Past disclosures · reporting ended (7)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AVEDRO INC
Report date November 21, 2019 · Filed November 25, 2019
Jointly reported with INTERWEST PARTNERS X LP, InterWest Management Partners X, LLC, ORONSKY ARNOLD L, NASR KHALED, Desai Keval
Section 16 reporting ended · disclosed 2019-11-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-11-21 · Other · Disposed 2,742,239 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F2: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2019-11-21 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-11-21 · Other · Disposed 3,005 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. F3: The securities are directly held by InterWest Venture Management Company ("IVMC"). Gilbert H. Kliman transferred these shares to IVMC for no consideration pursuant to a contractual agreement between Kliman and IW10. Arnold L. Oronsky and Gilbert H. Kliman are owners, directors and officers of IVMC and as such may be deemed to beneficially own the shares held by IVMC. Each of Arnold L. Oronsky and Gilbert H. Kliman disclaim beneficial ownership of such shares except to the extend of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share.
F2: The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F3: The securities are directly held by InterWest Venture Management Company ("IVMC"). Gilbert H. Kliman transferred these shares to IVMC for no consideration pursuant to a contractual agreement between Kliman and IW10. Arnold L. Oronsky and Gilbert H. Kliman are owners, directors and officers of IVMC and as such may be deemed to beneficially own the shares held by IVMC. Each of Arnold L. Oronsky and Gilbert H. Kliman disclaim beneficial ownership of such shares except to the extend of his pecuniary interest therein.
Doximity, Inc.
Report date August 02, 2022 · Filed August 05, 2022
Section 16 reporting ended · disclosed 2022-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 449,960 |
Reported balance
After 2022-08-02 transaction · row 1
1 source rowRow 1 · 2022-08-02 · Disposition to issuer · Disposed 4,714 · Balance 449,960 F1: Termination of restricted stock units, originally granted on July 27, 2022 pursuant to the Issuer's non-employee director compensation policy, due to Reporting Person's resignation from the Board of Directors on 8/2/2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Termination of restricted stock units, originally granted on July 27, 2022 pursuant to the Issuer's non-employee director compensation policy, due to Reporting Person's resignation from the Board of Directors on 8/2/2022.
Eiger BioPharmaceuticals, Inc.
Report date October 18, 2018 · Filed October 22, 2018
Jointly reported with INTERWEST PARTNERS X LP, InterWest Management Partners X, LLC, ORONSKY ARNOLD L, Desai Keval, NASR KHALED
Section 16 reporting ended · disclosed 2018-10-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,362,327 |
Last balance in matching sequence
After 2018-10-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-10-18 · Sale · Disposed 210,800 · Balance 1,388,792 F1: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.30 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. Row 2 · 2018-10-18 · Sale · Disposed 26,465 · Balance 1,362,327 F2: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.03 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. |
Filing footnotes · ownership attribution and instrument terms
F1: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.30 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F2: Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.03 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement.
PMV Pharmaceuticals, Inc.
Report date July 13, 2021 · Filed July 14, 2021
Jointly reported with INTERWEST PARTNERS X LP, InterWest Management Partners X, LLC, NASR KHALED, Desai Keval
Section 16 reporting ended · disclosed 2021-07-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,469,911 |
Reported balance
After 2021-07-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-07-13 · Other · Disposed 500,000 · Balance 4,469,911 F1: Represents pro rata in-kind distribution by InterWest Partners X, LP ("IW10") without consideration to its limited and general partners in accordance with the terms of the InterWest Partners X, LP Limited Partnership Agreement. Includes 97,632 shares distributed to InterWest Management Partners X, LLC ("IMP10") its general partner. |
| Common StockSEC Table I · non-derivative | IndirectBy: InterWest Management Partners X, LLC | 0 |
Last balance in matching sequence
After 2021-07-13 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2021-07-13 · Other · Acquired 97,632 · Balance 97,632 F1: Represents pro rata in-kind distribution by InterWest Partners X, LP ("IW10") without consideration to its limited and general partners in accordance with the terms of the InterWest Partners X, LP Limited Partnership Agreement. Includes 97,632 shares distributed to InterWest Management Partners X, LLC ("IMP10") its general partner. F3: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein. Row 3 · 2021-07-13 · Other · Disposed 97,632 · Balance 0 F2: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 3,642 shares distributed to Khaled A. Nasr ("Nasr"), 2,441 shares distributed to Keval Desai ("Desai") and 22,148 shares distributed to Gilbert H. Kliman ("Kliman"). F3: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein. |
| Common StockSEC Table I · non-derivative | IndirectBy: Khaled A. Nasr | 4,201 |
Reported balance
After 2021-07-13 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-07-13 · Other · Acquired 3,642 · Balance 4,201 F2: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 3,642 shares distributed to Khaled A. Nasr ("Nasr"), 2,441 shares distributed to Keval Desai ("Desai") and 22,148 shares distributed to Gilbert H. Kliman ("Kliman"). F3: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein. |
| Common StockSEC Table I · non-derivative | IndirectBy: Keval Desai | 2,816 |
Reported balance
After 2021-07-13 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-07-13 · Other · Acquired 2,441 · Balance 2,816 F2: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 3,642 shares distributed to Khaled A. Nasr ("Nasr"), 2,441 shares distributed to Keval Desai ("Desai") and 22,148 shares distributed to Gilbert H. Kliman ("Kliman"). F3: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein. |
| Common StockSEC Table I · non-derivative | IndirectBy Gilbert H. Kliman | 25,552 |
Reported balance
After 2021-07-13 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2021-07-13 · Other · Acquired 22,148 · Balance 25,552 F2: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 3,642 shares distributed to Khaled A. Nasr ("Nasr"), 2,441 shares distributed to Keval Desai ("Desai") and 22,148 shares distributed to Gilbert H. Kliman ("Kliman"). F3: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents pro rata in-kind distribution by InterWest Partners X, LP ("IW10") without consideration to its limited and general partners in accordance with the terms of the InterWest Partners X, LP Limited Partnership Agreement. Includes 97,632 shares distributed to InterWest Management Partners X, LLC ("IMP10") its general partner.
F2: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 3,642 shares distributed to Khaled A. Nasr ("Nasr"), 2,441 shares distributed to Keval Desai ("Desai") and 22,148 shares distributed to Gilbert H. Kliman ("Kliman").
F3: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein.
STAAR SURGICAL CO
Report date December 01, 2023 · Filed December 05, 2023
Section 16 reporting ended · disclosed 2023-12-05. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Venus Concept Inc.
Report date November 07, 2019 · Filed November 13, 2019
Section 16 reporting ended · disclosed 2019-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 658,657 |
Reported balance
After 2019-11-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-11-07 · Conversion · Acquired 301,605 · Balance 658,657 F1: Received in connection with the Agreement and Plan of Merger and Reorganization dated March 15, 2019, among the Issuer (formerly known as Restoration Robotics, Inc.), Radiant Merger Sub Ltd, an entity organized under the laws of Israel and Venus Concept Ltd, an entity organized under the laws of Israel (the "Merger"), upon the conversion of the outstanding principal and any accrued and unpaid interest of an 8% Convertible Promissory Notes issued by Venus Concept Inc., dated as of February 28, 2019 in the original principal amount of $2,000,000.00 and accrued interest income of $110,027.40. Share data reported herein reflects the 1-for-15 reverse stock split that occurred after the note conversion on November 7, 2019. F3: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664 prior to the 1-for-15 reverse stock split that occurred on November 7, 2019. F2: The securities are directly held by InterWest Partners IX, LP ("IW9"). InterWest Management Partners IX, LLC ("IMP9") as the general partner of IW9, may be deemed to beneficially own the shares held by IW9. The Reporting Person is a Managing Director of IMP9, and as such may be deemed to beneficially own the shares held by IW9. The Reporting Person disclaims beneficial ownership of such shares except to the extend of his pecuniary interest therein. The Reporting Person ceased to be a Director of the Issuer, and IW9 ceased to be a 10% owner of the Issuer, upon closing of the Merger. |
| Unsecured Subordinated Convertible Promissory NoteSEC Table II · derivative / convertible security · Expires 2020-08-28 | IndirectSee footnote | 0 |
Reported balance
After 2019-11-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-07 · Conversion · Disposed Not disclosed · Balance 0 F3: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664 prior to the 1-for-15 reverse stock split that occurred on November 7, 2019. F4: This Unsecured Subordinated Convertible Promissory Note converted upon the consummation of the Merger, pursuant to its terms. F2: The securities are directly held by InterWest Partners IX, LP ("IW9"). InterWest Management Partners IX, LLC ("IMP9") as the general partner of IW9, may be deemed to beneficially own the shares held by IW9. The Reporting Person is a Managing Director of IMP9, and as such may be deemed to beneficially own the shares held by IW9. The Reporting Person disclaims beneficial ownership of such shares except to the extend of his pecuniary interest therein. The Reporting Person ceased to be a Director of the Issuer, and IW9 ceased to be a 10% owner of the Issuer, upon closing of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Received in connection with the Agreement and Plan of Merger and Reorganization dated March 15, 2019, among the Issuer (formerly known as Restoration Robotics, Inc.), Radiant Merger Sub Ltd, an entity organized under the laws of Israel and Venus Concept Ltd, an entity organized under the laws of Israel (the "Merger"), upon the conversion of the outstanding principal and any accrued and unpaid interest of an 8% Convertible Promissory Notes issued by Venus Concept Inc., dated as of February 28, 2019 in the original principal amount of $2,000,000.00 and accrued interest income of $110,027.40. Share data reported herein reflects the 1-for-15 reverse stock split that occurred after the note conversion on November 7, 2019.
F2: The securities are directly held by InterWest Partners IX, LP ("IW9"). InterWest Management Partners IX, LLC ("IMP9") as the general partner of IW9, may be deemed to beneficially own the shares held by IW9. The Reporting Person is a Managing Director of IMP9, and as such may be deemed to beneficially own the shares held by IW9. The Reporting Person disclaims beneficial ownership of such shares except to the extend of his pecuniary interest therein. The Reporting Person ceased to be a Director of the Issuer, and IW9 ceased to be a 10% owner of the Issuer, upon closing of the Merger.
F3: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664 prior to the 1-for-15 reverse stock split that occurred on November 7, 2019.
F4: This Unsecured Subordinated Convertible Promissory Note converted upon the consummation of the Merger, pursuant to its terms.
Vyome Holdings, Inc
Report date August 06, 2019 · Filed August 08, 2019
Jointly reported with INTERWEST PARTNERS X LP, InterWest Management Partners X, LLC, ORONSKY ARNOLD L, Desai Keval, NASR KHALED
Section 16 reporting ended · disclosed 2019-08-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 380,224 |
Reported balance
After 2019-08-06 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-08-06 · Purchase · Acquired 25,000 · Balance 380,224 F1: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F2: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. |
| Warrants (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2024-08-05 | Direct | 18,750 |
Reported balance
After 2019-08-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-08-06 · Purchase · Acquired 18,750 · Balance 18,750 F1: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants. F2: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons purchased these shares directly from the underwriter in the Issuer's registered offering of Common Stock with 75% warrant coverage at a price of $4.00 per unit. There was no additional consideration paid for the warrants.
F2: These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, and are Venture Members of IMP10. Douglas Fisher, a Member of IMP10 is also a Director of the Issuer, and when required, files a separate Form 4 in his own name. All Reporting Persons disclaim beneficial ownership of shares of Obalon Therapeutics, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 21, 2026 00:11 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $25.77 | $0.00 |
DisclosureSEC source: 0001293171-26-000012 · form4-08212026_120845.xml · derivative · entry 3 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 2,500 shares Expires 2027-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 00:11 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 2,500 | $190.00 | $475,000.00 |
DisclosureSEC source: 0001293171-26-000012 · form4-08212026_120845.xml · nonDerivative · entry 2 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,406 F1 · balance_after: Includes 2,501 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 00:11 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 2,500 | $25.77 | $64,425.00 |
DisclosureSEC source: 0001293171-26-000012 · form4-08212026_120845.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,501 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 22:12 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 2,987 | $0.00 Strike: $53.57 | $0.00 |
DisclosureSEC source: 0001293171-26-000008 · form4-06012026_100608.xml · derivative · entry 2 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,987 Underlying: Common Stock · 2,987 shares Expires 2036-05-28 F3 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 22:12 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001293171-26-000008 · form4-06012026_100608.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,406 F1 · shares: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 4,609 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| May 28, 2026 Filed Jun 23, 2026 23:24 UTC Amendment | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 2,987 | $0.00 Strike: $106.52 | $0.00 |
DisclosureSEC source: 0001293171-26-000010 · form4a-06232026_110625.xml · derivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,987 Underlying: Common Stock · 2,987 shares Expires 2036-05-28 F1 · derivative.exercise_price: This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above. F2 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date. Read SEC document |
| May 14, 2026 Filed May 18, 2026 23:38 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $24.69 Strike: $24.69 | $123,450.00 |
DisclosureSEC source: 0001293171-26-000006 · form4-05182026_110531.xml · derivative · entry 3 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2026-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on June 2, 2016 and fully vested on the first anniversary of the grant date. Read SEC document |
| May 14, 2026 Filed May 18, 2026 23:38 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 5,000 | $140.76 | $703,800.00 |
DisclosureSEC source: 0001293171-26-000006 · form4-05182026_110531.xml · nonDerivative · entry 2 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,528 F1 · balance_after: Includes 2,731 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| May 14, 2026 Filed May 18, 2026 23:38 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 5,000 | $24.69 | $123,450.00 |
DisclosureSEC source: 0001293171-26-000006 · form4-05182026_110531.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,731 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| May 11, 2026 Filed May 13, 2026 23:52 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $24.69 Strike: $24.69 | $123,450.00 |
DisclosureSEC source: 0001293171-26-000004 · form4-05132026_110537.xml · derivative · entry 3 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2026-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on June 2, 2016 and fully vested on the first anniversary of the grant date. Read SEC document |
| May 11, 2026 Filed May 13, 2026 23:52 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 5,000 | $135.00 | $675,000.00 |
DisclosureSEC source: 0001293171-26-000004 · form4-05132026_110537.xml · nonDerivative · entry 2 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,528 F1 · balance_after: Includes 2,731 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| May 11, 2026 Filed May 13, 2026 23:52 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 5,000 | $24.69 | $123,450.00 |
DisclosureSEC source: 0001293171-26-000004 · form4-05132026_110537.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,731 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| January 02, 2026 Filed Jan 8, 2026 00:15 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 623 | $0.00 | $0.00 |
DisclosureSEC source: 0001293171-26-000002 · form4-01082026_120118.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,528 F1 · shares: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 2,731 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:20 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $24.69 Strike: $24.69 | $123,450.00 |
DisclosureSEC source: 0001293171-25-000003 · form4-12112025_091239.xml · derivative · entry 3 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2026-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on June 2, 2016 and fully vested on the first anniversary of the grant date. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:20 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 5,000 | $107.27 | $536,350.00 |
DisclosureSEC source: 0001293171-25-000003 · form4-12112025_091239.xml · nonDerivative · entry 2 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,905 F2 · price: This transaction was executed in multiple trades at prices ranging from $107.22 to $107.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 2,569 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:20 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 5,000 | $24.69 | $123,450.00 |
DisclosureSEC source: 0001293171-25-000003 · form4-12112025_091239.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,569 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:40 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 3,149 | $0.00 Strike: $94.87 | $0.00 |
DisclosureSEC source: 0001415889-25-015163 · form4-06022025_080635.xml · derivative · entry 3 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,149 Underlying: Common Stock · 3,149 shares Expires 2035-05-29 F5 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of the grant date. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:40 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 2,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015163 · form4-06022025_080635.xml · nonDerivative · entry 2 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,905 F3 · security: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F4 · balance_after: Includes 4,285 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| January 02, 2025 Filed Jun 2, 2025 20:40 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 461 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015163 · form4-06022025_080635.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,797 F1 · shares: Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 3.072 restricted stock units that have not vested or been delivered to the Reporting Person, as well as restricted stock units that have vested but delivery of which has been deferred by the Reporting Person. Read SEC document |
| December 20, 2024 Filed Dec 24, 2024 00:53 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $32.00 | $0.00 |
DisclosureSEC source: 0001415889-24-030109 · form4-12242024_121241.xml · derivative · entry 3 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The option exercises reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2024. F5 · derivative.exercise_date: This option was granted on July 23, 2015 and has a three-year vesting schedule in which one-third vests on each of the first three anniversaries of the grant date, such that the stock option vests in full on the three-year anniversary of the grant date. Read SEC document |
| December 20, 2024 Filed Dec 24, 2024 00:53 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 10,000 | $150.28 | $1,502,800.00 |
DisclosureSEC source: 0001415889-24-030109 · form4-12242024_121241.xml · nonDerivative · entry 2 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,336 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $150.00 to $150.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 2,611 restricted stock units that have not vested or been delivered to the Reporting Person. Read SEC document |
| December 20, 2024 Filed Dec 24, 2024 00:53 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 10,000 | $32.00 | $320,000.00 |
DisclosureSEC source: 0001415889-24-030109 · form4-12242024_121241.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,611 restricted stock units that have not vested or been delivered to the Reporting Person. Read SEC document |
| December 11, 2024 Filed Dec 14, 2024 00:50 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $32.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029374 · form4-12142024_121206.xml · derivative · entry 3 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 2,000 shares Expires 2025-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 23, 2015 and has a three-year vesting schedule in which one-third vests on each of the first three anniversaries of the grant date, such that the stock option vests in full on the three-year anniversary of the grant date. Read SEC document |
| December 11, 2024 Filed Dec 14, 2024 00:50 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 2,000 | $144.01 | $288,020.00 |
DisclosureSEC source: 0001415889-24-029374 · form4-12142024_121206.xml · nonDerivative · entry 2 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,336 F2 · price: This transaction was executed in multiple trades at prices ranging from $144.00 to $144.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 2,611 restricted stock units that have not vested or been delivered to the Reporting Person. Read SEC document |
| December 11, 2024 Filed Dec 14, 2024 00:50 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 2,000 | $32.00 | $64,000.00 |
DisclosureSEC source: 0001415889-24-029374 · form4-12142024_121206.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,611 restricted stock units that have not vested or been delivered to the Reporting Person. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 23:49 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $32.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023258 · form4-09112024_110919.xml · derivative · entry 4 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 3,000 shares Expires 2025-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on July 23, 2015 and has a three-year vesting schedule in which one-third vests on each of the first three anniversaries of the grant date, such that the stock option vests in full on the three-year anniversary of the grant date. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 23:49 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 1,000 | $130.00 | $130,000.00 |
DisclosureSEC source: 0001415889-24-023258 · form4-09112024_110919.xml · nonDerivative · entry 3 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,336 F1 · balance_after: Includes 2,611 restricted stock units that have not vested or been delivered to the Reporting Person. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 23:49 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 2,000 | $131.00 | $262,000.00 |
DisclosureSEC source: 0001415889-24-023258 · form4-09112024_110919.xml · nonDerivative · entry 2 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,336 F1 · balance_after: Includes 2,611 restricted stock units that have not vested or been delivered to the Reporting Person. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 23:49 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 3,000 | $32.00 | $96,000.00 |
DisclosureSEC source: 0001415889-24-023258 · form4-09112024_110919.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,611 restricted stock units that have not vested or been delivered to the Reporting Person. Read SEC document |
| May 30, 2024 Filed Jun 4, 2024 01:00 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantStock Option (Right to Buy) · Derivative | 1,246 | $0.00 Strike: $110.70 | $0.00 |
DisclosureSEC source: 0001415889-24-015246 · form4-06042024_010655.xml · derivative · entry 5 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,246 Underlying: Common Stock · 1,246 shares Expires 2034-05-30 F4 · derivative.exercise_date: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of the grant date. Read SEC document |
| May 30, 2024 Filed Jun 4, 2024 01:00 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $32.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015246 · form4-06042024_010655.xml · derivative · entry 4 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires 2025-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 23, 2015 and has a three-year vesting schedule in which one-third vests on each of the first three anniversaries of the grant date, such that the stock option vests in full on the three-year anniversary of the grant date. Read SEC document |
| May 30, 2024 Filed Jun 4, 2024 01:00 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015246 · form4-06042024_010655.xml · nonDerivative · entry 3 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,336 F2 · security: Represents a grant of restricted stock units received by the Reporting Person pursuant to the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F1 · balance_after: Includes 4,125 restricted stock units that have not vested or been delivered to the Reporting Person. Read SEC document |
| May 30, 2024 Filed Jun 4, 2024 01:00 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 5,000 | $112.00 | $560,000.00 |
DisclosureSEC source: 0001415889-24-015246 · form4-06042024_010655.xml · nonDerivative · entry 2 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,620 F1 · balance_after: Includes 4,125 restricted stock units that have not vested or been delivered to the Reporting Person. Read SEC document |
| May 30, 2024 Filed Jun 4, 2024 01:00 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 5,000 | $32.00 | $160,000.00 |
DisclosureSEC source: 0001415889-24-015246 · form4-06042024_010655.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4,125 restricted stock units that have not vested or been delivered to the Reporting Person. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:12 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $32.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007388 · form4-03082024_100313.xml · derivative · entry 5 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 5,000 shares Expires 2025-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted on July 23, 2015 and has a three-year vesting schedule in which one-third vests on each of the first three anniversaries of the grant date, such that the stock option vests in full on the three-year anniversary of the grant date. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:12 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 5,000 | $88.25 | $441,250.00 |
DisclosureSEC source: 0001415889-24-007388 · form4-03082024_100313.xml · nonDerivative · entry 4 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,620 F5 · price: This transaction was executed in multiple trades at prices ranging from $88.00 to $88.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: Includes 4,125 restricted stock units that have not yet vested or delivery of which has been deferred by the Reporting Person. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 22:12 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 5,000 | $32.00 | $160,000.00 |
DisclosureSEC source: 0001415889-24-007388 · form4-03082024_100313.xml · nonDerivative · entry 3 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes 4,125 restricted stock units that have not yet vested or delivery of which has been deferred by the Reporting Person. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:12 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 5,202 | $84.93 | $441,805.86 |
DisclosureSEC source: 0001415889-24-007388 · form4-03082024_100313.xml · nonDerivative · entry 2 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By InterWest Venture Management Company Disclosed balance after: 0 F3 · price: This transaction was executed in multiple trades at prices ranging from $84.50 to $85.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Consists of shares owned by InterWest Venture Management Company ("IVMC"). The Reporting Person is an officer, director and shareholder of IVMC and has sole voting and investment control over the shares held by IVMC. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:12 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 3,145 | $86.01 | $270,501.45 |
DisclosureSEC source: 0001415889-24-007388 · form4-03082024_100313.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By InterWest Venture Management Company Disclosed balance after: 5,202 F1 · price: This transaction was executed in multiple trades at prices ranging from $86.00 to $86.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Consists of shares owned by InterWest Venture Management Company ("IVMC"). The Reporting Person is an officer, director and shareholder of IVMC and has sole voting and investment control over the shares held by IVMC. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:52 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 8,000 | $92.00 | $736,000.00 |
DisclosureSEC source: 0001415889-24-005947 · form4-02292024_100237.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By InterWest Venture Management Company Disclosed balance after: 8,347 F1 · ownership.nature: Consists of shares owned by InterWest Venture Management Company ("IVMC"). The Reporting Person is an officer, director and shareholder of IVMC and has sole voting and investment control over the shares held by IVMC. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:37 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 895 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-000625 · form4-01042024_090142.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,620 F1 · security: Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 10,061 restricted stock units that have not yet vested or delivery of which has been deferred by the Reporting Person. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 22:59 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock | 366 | $32.99 | $12,074.34 |
DisclosureSEC source: 0001209191-23-057287 · doc4.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,457 Read SEC document |
| September 29, 2023 Filed Oct 4, 2023 00:08 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock | 435 | $40.18 | $17,478.30 |
DisclosureSEC source: 0001209191-23-051749 · doc4.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,091 Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 20:54 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.28 | $0.00 |
DisclosureSEC source: 0001415889-23-011933 · form4-08082023_080844.xml · derivative · entry 3 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on July 10, 2014 and had a three-year vesting schedule in which one-third vested on each of the first three anniversaries of the grant date. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 20:54 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 10,000 | $74.56 | $745,600.00 |
DisclosureSEC source: 0001415889-23-011933 · form4-08082023_080844.xml · nonDerivative · entry 2 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,725 F1 · balance_after: Includes 4,802 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 20:54 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 10,000 | $7.28 | $72,750.00 |
DisclosureSEC source: 0001415889-23-011933 · form4-08082023_080844.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4,802 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| June 15, 2023 Filed Jun 17, 2023 00:39 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 3,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038171 · doc4.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restrictions on the 3417 restricted shares of common stock lapse on the earlier of June 15, 2024 or the Corporation's 2024 Annual Meeting, subject to Dr. Kliman's continued service through that date. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 00:07 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 3,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009287 · form4-06062023_120649.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,725 F1 · security: Represents a grant of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 9,166 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:25 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000450 · form4-01042023_110107.xml · nonDerivative · entry 1 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,495 F1 · security: Represents a grant of restricted stock units received by the Reporting Person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 5,936 restricted stock units that have not vested or been delivered to the Reporting Person. Read SEC document |
| August 19, 2022 Filed Aug 19, 2022 20:00 UTC | GLAUKOS Corp GKOS · Entity 3510 | OtherCommon Stock | 2,382 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-029268 · doc4.xml · nonDerivative · entry 2 Kliman Gilbert H · CIK 0001293171 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By InterWest Venture Management Company Disclosed balance after: 16,347 F1 · kind: The Reporting Person transferred these shares to InterWest Venture Management Company ("IVMC") for no consideration, pursuant to an agreement between the Reporting Person and InterWest Partners X, LP ("IP10") relating to compensation received in connection with his service as director of the Issuer. F2 · ownership.nature: Consists of shares owned by IVMC. The Reporting Person is an officer, director and shareholder of IVMC and has sole voting and investment control over the shares held by IVMC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.